FDA rejects new obesity drug Qnexa

October 30, 2010

The US Food and Drug Administration has rejected a marketing request by Vivus for its new obesity treatment called Qnexa, because it considers it a health risk, the California-based biotech firm said in a statement.

The FDA issued a letter "to communicate its decision that the NDA (New Drug Application for Qnexa) cannot be approved in its present form," the company said.

In its decision, the FDA followed the July recommendations of its expert panel on endocrinological and metabolic drugs, who found by six votes to one abstention that Qnexa could cause potential heart problems.

Qnexa was the first obesity drug submitted to the FDA in a decade.

It combines two existing drugs, the appetite suppressant phentermine and topiramate, an anti-convulsant that can be used in conjunction with other drugs for weight loss.

The FDA on October 8 requested US pharmaceutical company Abbott Laboratories to pull its obesity drug Meridia from the US market after European tests found the key ingredient increased the risk of serious heart problems.

And last week, the US health panel rejected a marketing request for 2011 for weight-loss drug Lorcaserin, made by also California-based Arena Pharmaceuticals, after tests determined it caused tumors in laboratory rats.

While a high percentage of Americans are overweight or obese, there are few medical treatments, and those on the market can have side effects including increased and intestinal gas.

Explore further: FDA to review first of 3 new weight loss drugs

Related Stories

FDA to review first of 3 new weight loss drugs

July 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

Vivus weight loss drug faces FDA panel this week

July 13, 2010

(AP) -- Vivus Inc.'s experimental drug Qnexa was effective in cutting weight, the Food and Drug Administration said Tuesday, while acknowledging lingering concerns over the drug's nervous system and psychiatric side effects.

Experimental diet pill shows promise, little risk

July 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

FDA panel rejects experimental weight loss pill

July 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

Diet drugs face tough test before FDA

September 17, 2010

There has never been a magic prescription to help millions of obese Americans lose weight. Whether one is any closer to reality is now under scrutiny.

FDA rejects highly-anticipated diet drug Qnexa

October 29, 2010

(AP) -- Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...


Adjust slider to filter visible comments by rank

Display comments: newest first

5 / 5 (2) Oct 31, 2010
The FDA rightfully has declined the request of Vivus to market Qnexa.
We don't need another weight loss drug that has phentermine as a major component. The risk for coronary complications are just too great.
It is a risk that few physicians are willing to take anymore with their patients.
1 / 5 (2) Oct 31, 2010
People are proving they are pigs at the gut level. I agree some people are overweight due to medical reasons, but most just...pig-like, and they like it. Survival of the fittest should eliminate those genetic failures and make room for others, in my hopeful opinion.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.